Pain Management and the Opioid Epidemic PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Pain Management and the Opioid Epidemic PDF full book. Access full book title Pain Management and the Opioid Epidemic by National Academies of Sciences, Engineering, and Medicine. Download full books in PDF and EPUB format.
Author: National Academies of Sciences, Engineering, and Medicine Publisher: National Academies Press ISBN: 0309459575 Category : Medical Languages : en Pages : 483
Book Description
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Author: National Academies of Sciences, Engineering, and Medicine Publisher: National Academies Press ISBN: 0309459575 Category : Medical Languages : en Pages : 483
Book Description
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Author: Kimberly New Publisher: Hcpro, a Division of Simplify Compliance ISBN: 9781556459375 Category : Medical personnel Languages : en Pages : 0
Book Description
Drug Diversion Prevention in Healthcare Kimberly New, BSN, JD Theft of controlled substances at hospitals has always been a problem of paramount importance, but even with increased security measures, it still occurs. Drug Diversion Prevention in Healthcare discusses the issue of drug diversion in detail and demonstrates the components of a solid prevention plan. Loaded with tools and checklists, this book is designed to help hospital security officials create awareness of the drug diversion problem. You will learn how to design a program to keep staff accountable for drug administrations, as well as audits that monitor drug distribution from delivery to patient administration. This resource will help you: Establish an effective drug diversion prevention plan among hospital staff Understand the fundamental issues of drug diversion Create awareness among staff using tools and checklists Learn to recognize suspected diverters and mitigate problem areas in your hospital Effectively confront and deal with diverters in your facility
Author: United States. Congress. House. Committee on the Judiciary. Subcommittee on Crime Publisher: ISBN: Category : Political Science Languages : en Pages : 86
Author: National Academies of Sciences, Engineering, and Medicine Publisher: National Academies Press ISBN: 0309486483 Category : Medical Languages : en Pages : 175
Book Description
The opioid crisis in the United States has come about because of excessive use of these drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use disorder (OUD). More than 2 million people in the United States are estimated to have OUD, which is caused by prolonged use of prescription opioids, heroin, or other illicit opioids. OUD is a life-threatening condition associated with a 20-fold greater risk of early death due to overdose, infectious diseases, trauma, and suicide. Mortality related to OUD continues to escalate as this public health crisis gathers momentum across the country, with opioid overdoses killing more than 47,000 people in 2017 in the United States. Efforts to date have made no real headway in stemming this crisis, in large part because tools that already existâ€"like evidence-based medicationsâ€"are not being deployed to maximum impact. To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, this report studies the evidence base on medication assisted treatment (MAT) for OUD. It examines available evidence on the range of parameters and circumstances in which MAT can be effectively delivered and identifies additional research needed.
Author: Matthew B. Robinson Publisher: SUNY Press ISBN: 1438448384 Category : Political Science Languages : en Pages : 330
Book Description
Revised and updated edition that analyses how the Office of National Drug Control Policy employs statistics to misleadingly claim the War on Drugs is a success. First published in 2007, Lies, Damned Lies, and Drug War Statistics critically analyzed claims made by the Office of National Drug Control Policy (ONDCP), the White House agency of accountability in the nations drug war since 1989, as found in the six editions of the annual National Drug Control Strategy between 2000 and 2005. In this revised and updated second edition of their critically acclaimed work, Matthew B. Robinson and Renee G. Scherlen examine seven more recent editions (20062012) to once again determine if ONDCP accurately and honestly presents information or intentionally distorts evidence to justify continuing the drug war. They uncover the many ways in which ONDCP manipulates statistics and visually presents that information to the public. Their analysis demonstrates a drug war that consistently fails to reduce drug use, drug fatalities, or illnesses associated with drug use; fails to provide treatment for drug-dependent users; and drives up the prices of drugs. They conclude with policy recommendations for reforming ONDCPs use of statistics, as well as how the nation fights the war on drugs. Praise for the First Edition Lies, Damned Lies, and Drug War Statistics is surprisingly easy to read, and Robinson and Scherlen have done a huge favor not only to critics of current drug policy by compiling this damning critique of ONDCP claims, but also to anyone interested in how data is compiled, presented, and misused by bureaucrats attempting to guard their domains. It should be required reading for members of Congress. Drug War Chronicle Book Review The authors have performed a valuable service to our democracy with their meticulous analysis of the White House ONDCP public statements and reports. They have pulled the sheet off what appears to be an official policy of deception using clever and sometimes clumsy attempts at statistical manipulation. This document, at last, gives us a map of the truth. Mike Gray, author of Drug Crazy: How We Got into This Mess and How We Can Get Out Robinson and Scherlen make a valuable contribution to documenting how ONDCP fails to live up to basic standards of accountability and consistency. Ethan Nadelmann, Executive Director, Drug Policy Alliance
Author: Publisher: DIANE Publishing ISBN: 1437930441 Category : History Languages : en Pages : 77
Book Description
This is a print on demand edition of a hard to find publication. The original Nat. Southwest Border Counter-Narcotics Strategy (2007) focused primarily on what the entities of the U.S. Fed. Gov¿t. could do to prevent the illegal trafficking of drugs across the border with Mexico. As the cartels battle the Mexican Gov¿t. and one another, we have seen significant disruptions in the availability of such drugs as cocaine and meth in U.S. markets. The new Strategy recognizes the role that the outbound flow of illegal cash and weapons plays in sustaining the cartels and addresses this threat. Contents: Intelligence and Info. Sharing; At the Ports of Entry; Between the Ports of Entry; Air and Marine; Investigations and Prosecutions; Money; Weapons; Technology; Cooperation with Mexico; Tunnel Strategy; Resources. Illus.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309269393 Category : Medical Languages : en Pages : 377
Book Description
The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.
Author: National Academies of Sciences, Engineering, and Medicine
Author: National Academies of Sciences, Engineering, and Medicine
Author: United States. Department of Justice
Author: Kimberly New
Author: 
Author: United States. General Accounting Office
Author: United States. Congress. House. Committee on the Judiciary. Subcommittee on Crime
Author: National Academies of Sciences, Engineering, and Medicine
Author: Matthew B. Robinson
Author: 
Author: Institute of Medicine